Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/29/2871615/0/en/Arcutis-to-Report-First-Quarter-2024-Financial-Results-and-Host-Conference-Call-on-May-14-2024.html
https://www.globenewswire.com/news-release/2024/04/10/2860677/0/en/Arcutis-Appoints-David-Topper-as-Chief-Financial-Officer.html
https://in.investing.com/news/arcutis-biotherapeutics-appoints-new-cfo-to-bolster-commercial-operations-93CH-4118057
https://www.globenewswire.com/news-release/2024/04/05/2858723/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/03/28/2853943/0/en/Arcutis-to-Present-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2024/03/11/2843742/0/en/Arcutis-Promotes-Todd-Tucker-to-Chief-Human-Resources-Officer.html
https://www.globenewswire.com/news-release/2024/03/10/2843436/0/en/Arcutis-Presents-Late-Breaking-Data-From-INTEGUMENT-PED-Phase-3-Trial-of-Roflumilast-Cream-0-05-in-Atopic-Dermatitis-in-Children-Ages-2-to-5-at-the-American-Academy-of-Dermatology-.html
https://www.globenewswire.com//news-release/2024/03/05/2840864/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/03/04/2839947/0/en/Arcutis-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-by-Underwriters-of-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com//news-release/2024/03/04/2839551/0/en/Arcutis-Announces-Acceptance-of-Late-Breaking-Abstract-in-Atopic-Dermatitis-Among-Five-New-Topical-Roflumilast-Data-Being-Presented-at-the-American-Academy-of-Dermatology-Annual-Me.html